secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001171843-25-001757
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeyondSpring FY2024 net loss $8.9M; Plinabulin Phase 3 shows OS benefit in NSCLC
--------------------------------------------------------------------------------

- Net loss from continuing ops $8.9M vs $14.0M in 2023; R&D expenses fell to $2.6M from $7.3M.
- Plinabulin Phase 3 data published in Lancet Respiratory Medicine: statistically significant overall survival benefit in 2L/3L NSCLC EGFR wild-type vs docetaxel.
- Agreement to sell portion of SEED shares for ~$35.4M gross proceeds; first close of $7.35M in Feb 2025.
- SEED entered Eisai research collaboration with potential payments up to $1.5B; completed $24M Series A-3 first close led by Eisai.
- SEED's RBM39 degrader ST-01156 granted Rare Pediatric Disease and Orphan Drug Designations by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/0001171843-25-001757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/f8k_032725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer